A signal of cardiovascular harm with rosiglitazone led to a new FDA policy on diabetes-drug approval. As that signal has faded in recent analyses, should FDA policy change?
No takes yet. Share an insight, caveat, or question.
Hiatt et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: